从aflibercept切换到faricimab后的现实世界结果在患有糖尿病黄斑的眼睛中
Kim Lien Huber1, Heiko Stino1, Irene Steiner2
1Medical University of Vienna, Department of Ophthalmology, Vienna, Austria.
Investigative ophthalmology & visual science
|December 31, 2024
概括
将糖尿病黄斑 (DME) 患者从阿弗利塞普特转换为法里西马布显示出积极的结果. 在大多数眼睛中,法里西马布有助于减少或稳定DME,而那些先前对aflibercept有反应的人的结果更好.
科学领域:
- 眼科医生 眼科 眼科
- 视网膜疾病 视网膜疾病
- 药理学 药理学是指药理学的学科.
背景情况:
- 糖尿病黄斑 (DME) 是糖尿病患者视力丧失的主要原因.
- 内阿弗利塞普特是一种常见的DME治疗方法,但有些患者可能没有充分的反应或需要频繁的注射.
- 评估像法里西马布这样的替代治疗方法对于优化DME管理至关重要.
研究的目的:
- 评估在糖尿病黄斑胀 (DME) 患者中从静脉直肠阿弗利塞普切换到法里西马布的有效性.
- 为了比较以前对aflibercept有反应的眼睛 (rDME) 和没有反应的眼睛 (nrDME) 的解剖和功能结果.
主要方法:
- 一个回顾性干预研究,对52只眼睛进行了DME的研究,这些眼睛从aflibercept转换为faricimab.
- 根据对aflibercept的反应,患者根据中央子场厚度 (CST) 分类为rDME或nrDME.
- 费里西马布是通过加重剂量,然后是治疗和延长疗程进行的,结果在转换后12周评估结果.
主要成果:
- 在12周后,54%的rDME和25%的nrDME眼睛实现了CST降低>20%或CST≤250微米.
- 视力敏度 (VA) 在两组都得到改善,rDME显示出更好的结果 (0.22 logMAR vs 0.36 logMAR).
- 较长的治疗间隔 (≥8周) 在rDME组 (73%) 与nrDME组 (47%) 相比,在rDME组更频繁地实现.
结论:
- 转换为法里西马布导致大多数眼睛的DME减少或稳定,无论之前的aflibercept反应如何.
- 以前对aflibercept (rDME) 反应的眼睛表现出优异的解剖反应,并使法里西马布的治疗间隔更早,更长.
- 法里西马布代表了对DME患者的可行的治疗选择,为延长剂量间隔提供了潜在的可能性.
更多相关视频
08:10An Ex Vivo Tissue Culture Model for Fibrovascular Complications in Proliferative Diabetic Retinopathy
Published on: January 25, 2019
7.7K
05:14Author Spotlight: Overcoming Anti-VEGF Resistance Through Advanced Vascular Morphology Assessment in Choroidal Neovascularization
Published on: August 11, 2023
961
相关概念视频
01:27Open Angle Glaucoma: Treatment
In open-angle glaucoma, the iridocorneal angle remains open, but the trabecular meshwork becomes stiff, slowing down the outflow of aqueous humor. This causes a buildup of aqueous humor in the anterior chamber, leading to a sudden increase in intraocular pressure. The treatment for open-angle glaucoma focuses on reducing the elevated intraocular pressure by either decreasing the secretion of aqueous humor or increasing its outflow.
Drugs such as carbonic anhydrase inhibitors, α2- and...
Drugs such as carbonic anhydrase inhibitors, α2- and...
01:27Diabetic Retinopathy
DefinitionDiabetic retinopathy is a microvascular complication of diabetes affecting the retinal blood vessels.Risk FactorsDiabetic retinopathy is present in almost all individuals with type 1 diabetes and more than 60% of those with type 2 diabetes after two decades of disease.The risk increases with poor glycemic control, hypertension, dyslipidemia, smoking, pregnancy, and puberty.Although cataracts and glaucoma are also more frequent in people with diabetes, retinopathy remains the leading...